Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis

Tuberculosis (TB) is responsible for enormous global morbidity and mortality, and current treatment regimens rely on the use of drugs that have been in use for more than 40 years. Owing to widespread resistance to these therapies, new drugs are desperately needed to control the TB disease burden. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Anh T., Watson, Emma E., Pujari, Venugopal, Conroy, Trent, Dowman, Luke J., Giltrap, Andrew M., Pang, Angel, Wong, Weng Ruh, Linington, Roger G., Mahapatra, Sebabrata, Saunders, Jessica, Charman, Susan A., West, Nicholas P., Bugg, Timothy D. H., Tod, Julie, Dowson, Christopher G., Roper, David I., Crick, Dean C., Britton, Warwick J., Payne, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337940/
https://www.ncbi.nlm.nih.gov/pubmed/28248311
http://dx.doi.org/10.1038/ncomms14414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337940/
https://www.ncbi.nlm.nih.gov/pubmed/28248311
http://dx.doi.org/10.1038/ncomms14414

Ejemplares similares